Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation
John W. Eikelboom(Population Health Research Institute), Salim Yusuf(Population Health Research Institute), Hans‐Christoph Diener(University of Birmingham), Marco Alings(Utrecht University), Sean Yang(Population Health Research Institute), Jeanne Varrone(Boehringer Ingelheim (United States)), Scott Kaatz(Hurley Medical Center), Lars Wallentin(Uppsala University), Kurt Huber(Sigmund Freud Privatuniversität Wien), Stuart J. Connolly(Population Health Research Institute), Jonas Oldgren(Uppsala University), Maria Grazia Franzosi(Goethe University Frankfurt), Mike Ezekowitz(Goethe University Frankfurt), Stefan H. Hohnloser(Goethe University Frankfurt), Paul Reilly(Boehringer Ingelheim (United States)), Jeff S. Healey(Population Health Research Institute)
Cited by 1,079
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
|New England Journal of Medicine|2015|5.1k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k